Skip to content
CompletedEarly Phase 1

Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study

NCT01951508 · University Hospital, Basel, Switzerland

Closed to entry
Status
Not accepting participants
Early Phase 1
Phase
24
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The purpose of this study is to investigate effects of methylphenidate, modafinil, and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") on emotion-processing and cognitive performance using functional magnetic resonance imaging (fMRI) techniques. The primary hypothesis is that these psychostimulants differentially affect processing of emotional stimuli and potentially leading to alterations in social cognition and behavior.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Effect on amygdala and striatum BOLD signal responses to emotional stimuli

    Measured over 1.5h

  • Effects on cognitive performance and associated BOLD signal changes in frontal areas

    Measured over 1.5h

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 45 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * Age between 18 and 45 years * Sufficient understanding of the German language * Subjects understand the procedures and the risks associated with the study * Participants must be willing to adhere to the protocol and sign the consent form * Participants must be willing to refrain from taking illicit psychoactive substances including cannabis during the study * Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session, as well as during the study day * Participants must be willing not to drive a traffic vehicle within 24h following MDMA administration * Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session. * Body mass index: 18-27kg/m2 Exclusion Criteria: * Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>140/90mmgHg) or Hypotension (SBP\<85mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder. This also includes contraindications for MRI scanning (any type of implants such as heart pacer, insulin-pump, cochlea-implants, heart valve) * Current or previous psychotic or major affective disorder * Psychotic or major affective disorder in first-degree relatives * Prior illicit drug use (except tetrahydrocannabinol (THC)-containing products) more than 5 times or any time within the previous 2 months * Pregnant or nursing women * Participation in another clinical trial (currently or within the last 30days) * Use of medications that are contraindicated or otherwise interfere with the effects of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc. ) * Tobacco smoking (regularly \> 10cigarettes / day)

Where

1 study site

FacilityCityRegionCountry
University Hospital BaselBaselCanton of Basel-CitySwitzerland

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT01951508 on ClinicalTrials.gov →

Last updated in the registry 2016-01-21. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits